Resomelagon (AP1189) acetate is a potent, orally active melanocortin receptor (MR) agonist about MC 1 and MC 3 . Resomelagon acetate induces ERK1/2 phosphorylation and Ca 2+ mobilization. Resomelagon acetate has anti-inflammatory activity. Resomelagon acetate can be used for obesity and chronic inflammation research In Vitro Resomelagon acetate (0-1000 μM; 8 min; HEK293A cells) promotes melanocortin signal transduction through ERK1/2 phosphorylation and Ca 2+ mobilization. Resomelagon acetate (1 nM; 30 min; peritoneal macrophages) has anti-inflammatory activity and inhibits TNF-α release and efferocytosis. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Resomelagon acetate (0-10 mg/kg; i.p., i.v. and p.o.; for 24 h; male C57BL/6J wild-type (WT) and BALB/c mice) promotes resolution of acute inflammation in vivo . Resomelagon acetate (25-50 mg/kg; p.o.; daily, for 8 d; male C57BL/6J wild-type (WT) and BALB/c mice) reduces arthritis in mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:Targrt: MC1 and MC3